Back to top

Analyst Blog

 

ArQule Inc. (ARQL - Snapshot Report) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with Pfizer’s (PFE - Analyst Report) Camptosar (irinotecan) and Bristol-Myers Squibbs/Eli Lilly’s (BMY/LLY) Erbiutx (cetuximab) in patients with refractory or relapsed colorectal cancer (CRC). 
 
The study failed to meet its key endpoint of progression-free survival (PFS) - median PFS was 8.3 months in the tivantinib arm compared with 7.3 months in the control arm (irinotecan and cetuximab plus placebo). The secondary endpoint of objective response rate (ORR) was also not statistically significant compared to the control arm (45% versus 33%).   
 
The disappointing news led to an 11.6% decline in the stock price. We note that this is the second setback for ArQule after the discontinuation of the MARQUEE (M et inhibitor ARQ 197 plus E rlotinib versus E rlotinib plus placebo in non-squamous non-small cell lung cancer {NSCLC}) study. In Oct 2012, ArQule had announced that the independent Data Monitoring Committee recommended that the phase III MARQUEE study should be discontinued as it was not likely to meet its primary endpoint of improved overall survival. MARQUEE was a pivotal study which was conducted under a special protocol assessment to evaluate tivantinib in combination with Roche’s (RHHBY - Analyst Report) Tarceva (erlotinib) in previously treated patients with locally advanced or metastatic, non-squamous NSCLC. 
 
Given the recent pipeline setbacks, we prefer to be on the sidelines and hence, have a Neutral recommendation on ArQule which carries a Zacks Rank #3 (Hold). 
 
Right now, Medivation, Inc. (MDVN) looks attractive with a Zacks Rank #1 (Strong Buy). 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%